CSPC Pharmaceutical Group Limited
CSPCY | OTC
$4.07
+$0.13 (+3.30%)
Nov 2, 2026, 10:20 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q4 2025 Dec 31, 2025 | Q2 2025 Jun 30, 2025 | Q4 2024 Dec 31, 2024 | Q2 2024 Jun 30, 2024 | Q4 2023 Dec 31, 2023 | Q2 2023 Jun 30, 2023 | Q4 2022 Dec 31, 2022 | Q2 2022 Jun 30, 2022 | Q4 2021 Dec 31, 2021 | Q2 2021 Jun 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 30.86B | 25.54B | 25.98B | 29.38B | 31.45B | 31.84B | 31.9B | 31.19B | 29.96B | 27.67B | 25.69B |
Cost of Revenue | 8.68B | 8.79B | 8.63B | 8.82B | 9B | 9.39B | 9.4B | 8.75B | 7.79B | 6.68B | 6.28B |
Gross Profit | 22.17B | 16.75B | 17.35B | 20.55B | 22.45B | 22.44B | 22.5B | 22.44B | 22.16B | 20.99B | 19.41B |
Operating Income | 8.62B | 3.9B | 4.21B | 5.41B | 7.16B | 7.08B | 5.09B | 5.02B | 6.67B | 6.2B | 5.91B |
Interest Income | 189.85M | 192.37M | 202.68M | 109.75M | n/a | n/a | n/a | n/a | 131M | 221M | 177.39M |
Pretax Income | 9.09B | 4.72B | 4.87B | 5.64B | 7.46B | 7.47B | 5.63B | 5.61B | 6.98B | 6.8B | 7B |
Net Income | 7.32B | 3.81B | 3.83B | 4.38B | 5.89B | 5.94B | 4.53B | 4.49B | 5.57B | 5.57B | 5.8B |
Selling & General & Admin | 7.49B | 7.21B | 5.55B | 7.56B | 10.26B | 10.49B | 8.44B | 8.92B | 11.76B | 11.38B | 10.5B |
Research & Development | 6.06B | 5.71B | 5.33B | 5.26B | 5.03B | 4.88B | 4.48B | 4.01B | 3.74B | 3.41B | 2.99B |
Other Expenses | n/a | -60.54M | 2.26B | 2.32B | n/a | n/a | 2.66B | 2.66B | n/a | n/a | n/a |
Operating Expenses | 13.55B | 12.85B | 13.14B | 15.14B | 15.29B | 15.36B | 15.58B | 15.6B | 15.5B | 14.79B | 13.5B |
Interest Expense | 29.79M | 37.9M | 43.34M | 22.11M | 9.02M | 15.31M | 24.32M | 24.89M | 10.35M | 9.23M | 13.39M |
Selling & Marketing Expenses | n/a | 3.05B | 4.9B | 1.85B | n/a | n/a | 2.49B | 2.49B | n/a | n/a | n/a |
Cost & Expenses | 22.23B | 21.64B | 21.77B | 23.97B | 24.29B | 24.76B | 24.99B | 24.34B | 23.29B | 21.47B | 19.78B |
Income Tax Expense | 1.44B | 914.82M | 1.03B | 1.26B | 1.43B | 1.33B | 963.38M | 1.03B | 1.31B | 1.15B | 1.13B |
Shares Outstanding (Basic) | 11.4B | 11.52B | 11.43B | 11.64B | 11.84B | 11.85B | 11.89B | 11.93B | 11.92B | 11.95B | 11.95B |
Shares Outstanding (Diluted) | 11.42B | 11.52B | 11.43B | 11.64B | 11.84B | 11.85B | 11.89B | 11.93B | 11.92B | 11.95B | 11.96B |
EPS (Basic) | 0.65 | 0.34 | 0.33 | 0.37 | 0.50 | 0.50 | 0.52 | 0.52 | 0.47 | 0.47 | 0.49 |
EPS (Diluted) | 0.65 | 0.34 | 0.33 | 0.37 | 0.50 | 0.50 | 0.52 | 0.52 | 0.47 | 0.47 | 0.49 |
EBITDA | 9.98B | 5.85B | 6.36B | 7.13B | 8.79B | 8.68B | 8.83B | 8.73B | 7.89B | 7.65B | 7.84B |
EBIT | 8.62B | 4.47B | 4.96B | 5.78B | 7.58B | 7.55B | 7.71B | 7.68B | 6.97B | 6.79B | 7.01B |
Depreciation & Amortization | 1.36B | 1.38B | 1.4B | 1.35B | 1.21B | 1.13B | 1.11B | 1.05B | 924.22M | 857.74M | 831.43M |
Add to Watchlist
Select watchlists to add or remove CSPCY